Human nature meets technology in MedTech sales

Tern plc

Sales teams are asked to master products that change lives, yet the way they are trained rarely matches the complexity or urgency of the task. The numbers tell a familiar story, long onboarding times, high turnover, and widespread target misses. But beneath the statistics lies a deeper truth: much of what is taught simply does not stick.

The core issue is human nature itself. Our brains are wired to forget what we do not actively apply. Traditional sales education, the manuals, the workshops, the static presentations, leans on outdated methods that assume information can be absorbed through repetition.

The shift now underway is about changing how people learn. Artificial Intelligence, Mixed Reality, and Augmented Reality are converging to create environments where knowledge becomes experience. Instead of reading about a medical device, a sales representative can manipulate it holographically, exploring every function and feature in three dimensions. Instead of rehearsing sales pitches in abstract, they can engage with realistic AI-driven simulations that replicate the tension and unpredictability of real clinical conversations.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Search